Studies whether complement activation signals severity of IgA nephropathy
Observes complement activity as a marker of kidney disease in adults with IgA nephropathy.
Plain-language title generated from the registry record
Registry title: Study of the Link Between Complement Activation and IgA Nephropathy Severity
Key facts
- Where
- Strasbourg, FranceSee the site
Where in France
- Service de néphrologieStrasbourg, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Strasbourg, France
- Trial code
- NCT05234463
- Record updated
- 19 August 2026
- Original description
ICONE study (IgA Complement and NEphropathy is a prospective monocentric observational study.Read full original descriptionShow less
Study of the Link Between Complement Activation and IgA Nephropathy Severity
ICONE study (IgA Complement and NEphropathy is a prospective monocentric observational study.
The main objective is to evaluate the relevance of complement activation as a biomarker of disease severity and progression in patients with a biopsy proven IgAN.
Inclusion: Adult patients, male or female, with a biopsy proven IgA nephropathy; Primitive and secondary forms can be included; Regardless of the date of diagnosis and the level of kidney function; With or without past of kidney transplantation; Followed in the Nephrology Department, Strasbourg University Hospital; Signed informed consent.
Exclusion: Active or recent infectious or inflammatory syndrome (<2 months), recent vaccination (<2 months), ongoing acute humoral rejection treatment, treatment with plasma exchanges (<2 months), current treatment with complement inhibitors; Impossibility of giving informed information (emergency situation, difficulties in understanding, etc.); Subject under safeguard of justice, guardianship or curatorship.